BioSpace News Archive

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has released its annual letter to shareholders. In the shareholder letter Angelos Stergiou, MD, ScD h.c., SELLAS’ President & Chief Executive Officer, addresses the Company’s product development, ant

BVI, a leading developer, manufacturer, and marketer of surgical devices for the ophthalmic marketplace, announced that it has named David Murray as Chief Financial Officer.

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company’s website. The report summarizes the company’s business operations, strategy and financial results. The annual report is available as a PDF version on the company’s website below; www.oncopeptides.com / Inve

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 6, 2020, to discuss its first quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.

Production and launch of the test kit RT-PCR COVID-19 Thai Duong will take place at the end of April 2020 and are carried out by Vietnamese science and technology company SUNSTAR Joint Stock Company.

Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, that Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has exercised an option through the parties’ drug discovery collaboration to identify new small molecule-ba

In the six weeks since ARUP Laboratories became the first clinical laboratory in Utah and one of the first in the nation to offer COVID-19 molecular diagnostic testing, ARUP has performed more than 40,000 tests in Utah alone and its tests have identified 55 percent of COVID-19-positive individuals in the state.

Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation of our sequencing systems and related consumables intended to expand SARS-CoV-2 sequencing capabilities and capacity in ten African countries, including the Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Mali, Nig

- Now available in a third vial size (3-mL - 900-IU), HyperRAB, the only high-potency formulation of rabies immunoglobulin, gives healthcare professionals more convenient dosing options, reduces storage space and minimizes unnecessary waste - HyperRAB is presently the number one prescribed rabies immunoglobulin in the U.S., with over 1 billion international units administered to more than 1 million patients over 45 years - Grifols continues to expand its leadership in disease

VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that the Company’s annual financial statements and management discussion and analysis for the year ended December 31, 2019 are now available to download on the Company’s website at www.vaxil-bio.com/ and on Sedar at www.sedar.com . The following is a summary